The Efficacy And Safety Of Recombinant Insulin Lispro And Insulin Glargine Combined Injection In Treatment Of Type 2 Diabetes

Objective:To compare the efficacy and safety of recombinant insulin lispro (Wan bang) and insulin lispro (Lilly) injection in the treatment of Type 2 diabetic patients.Methods:Patients with T2DM were randomly assigned to test group (recombinant insulin lispro group) (n=32) and control group (lispro group) (n=16);test group received premeal recombinant insulin lispro plus bedtime insulin glargine injection; control group received premeal insulin lispro plus bedtime insulin glargine Injection; the period of treatment was 16 weeks. HbA1c,2 hour postprandial blood glucose, fasting plasma glucose, blood routine test, urine routine test, liver function, kidney function, blood lipids, insulin antibody, weight, waistline, hipline, systolic blood pressure, diastolic blood pressure were measured in pre-treatment and after-treatment; the insulin dose, adverse events and the incidence of hypoglycemic events were compared at the end of treatment.Results:The forty-four subjects finished the study. The twenty-eight subjects finished in the test group and sixteen subjects finished in the control group; After 16 weeks of treatment, the levels of HbAlc, FPG and 2hPG were decreased significantly in the two groups (P<0.05), and there were no difference of reduction of A1C, FBG,2hPG in two groups (P> 0.05); the blood lipids did not change significantly at pre-treatment and after-treatment in the test group, while TC and LDL-C had a declining trend (P<0.05) in the control group, BMI and WHR were increased compared to the baseline (P<0.05)in the test group; the BMI of control group was increasing, but there was not statistically significant. WHR were increased compared to the baseline (P<0.05) in the control group, there was no significant difference between the two groups in the increase degree of weight (P>0.05).There was no significant difference between the two groups in the change of blood routine test, liver function, kidney function and blood pressure after the treatment. there was no significant difference between the two groups in incidence of hypoglycemic events. No severe hypoglycemia happened during the period of treatment.Conclusion:Compared the Recombinant insulin lispro injection (WanBang) with lispro insulin injection (Lilly), they had the same efficacy and safety.